GSK: extends collaboration with US firm Vir Biotechnology
(CercleFinance.com) - GSK and the San Francisco firm Vir Biotechnology are expanding their coronavirus collaboration to include new treatments for influenza and other respiratory viruses, the companies said on Wednesday.
The move provides GSK with the exclusive rights to develop monoclonal antibodies for the prevention or treatment of influenza, including VIR-2482, an intramuscularly prophylactic that has completed a Phase 1 trial.
The British drugmaker said it will have an exclusive option to jointly develop the product after Vir completes and reports Phase 2 trial outcomes.
Under the terms of the deal, GSK will make an upfront payment of 225 million dollars, and a further equity investment of 120 million dollars in Vir.
In addition, the companies said they will also engage in two additional research programs, expanding their current genomics collaboration to develop potential pan-coronavirus therapeutics to now include other respiratory virus targets.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The move provides GSK with the exclusive rights to develop monoclonal antibodies for the prevention or treatment of influenza, including VIR-2482, an intramuscularly prophylactic that has completed a Phase 1 trial.
The British drugmaker said it will have an exclusive option to jointly develop the product after Vir completes and reports Phase 2 trial outcomes.
Under the terms of the deal, GSK will make an upfront payment of 225 million dollars, and a further equity investment of 120 million dollars in Vir.
In addition, the companies said they will also engage in two additional research programs, expanding their current genomics collaboration to develop potential pan-coronavirus therapeutics to now include other respiratory virus targets.
Copyright (c) 2021 CercleFinance.com. All rights reserved.